(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kinase inhibitor lapatinib can induce a compensatory HER3 increase, which may attenuate antitumor efficacy. Therefore, we explored in vivo HER3 tumor status assessment after lapatinib treatment with zirco...

Descripción completa

Detalles Bibliográficos
Autores principales: Pool, Martin, Kol, Arjan, de Jong, Steven, de Vries, Elisabeth G. E., Lub-de Hooge, Marjolijn N., Terwisscha van Scheltinga, Anton G.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680796/
https://www.ncbi.nlm.nih.gov/pubmed/28873009
http://dx.doi.org/10.1080/19420862.2017.1371382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680796/
https://www.ncbi.nlm.nih.gov/pubmed/28873009
http://dx.doi.org/10.1080/19420862.2017.1371382

Ejemplares similares